Chief executive of Array BioPharma resigns

Chairman Kyle Lefkoff will lead effort to replace Robert Conway

Robert Conway has resigned as chief executive of Array BioPharma, a US biotechnology company, for personal reasons. The board has appointed chairman Kyle Lefkoff to serve as executive chairman to oversee the company in the interim and lead the effort to identify a new chief executive.

Lefkoff said he will work with the Array management team to ensure a smooth transition and continued advancement of the company’s multiple clinical programmes in cancer and inflammation and supporting our many partnered programmes.

You may also like

Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Finance

Array BioPharma to cut jobs in restructure

Will focus on development of key clinical programmes
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
Regulatory
What is ISO/IEC 17025 and why it matters for calibration

What is ISO/IEC 17025 and why it matters for calibration

As regulatory expectations continue to increase, particularly around data integrity and traceability, the question becomes less about collecting data, and more about trusting it
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Neuland Laboratories announces new $20m process development lab in Hyderabad

Neuland Laboratories announces new $20m process development lab in Hyderabad

The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
Regulatory
FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs

FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs

GSK and Spero Therapeutics' tebipenem pivoxil matches IV imipenem-cilastatin in Phase III trials, offering an outpatient alternative for resistant infections that cost the US healthcare system more than $6bn annually
Subscribe now